Education
About Us
Working with TipRanks
Follow Us
Q32 Bio (QTTB)
NASDAQ:QTTB
Total Valuation
Q32 Bio has a market cap or net worth of $39.37M. The enterprise value is -$7.78M.
Market Cap$39.37M
Enterprise Value-$7.78M
Share Statistics
Q32 Bio has 12,304,352 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,304,352
Owned by Insiders2.27%
Owned by Institutions61.71%
Financial Efficiency
Q32 Bio’s return on equity (ROE) is -8.41 and return on invested capital (ROIC) is -83.11%.
Return on Equity (ROE)-8.41
Return on Assets (ROA)-0.52
Return on Invested Capital (ROIC)-83.11%
Return on Capital Employed (ROCE)-0.87
Revenue Per Employee0.00
Profits Per Employee-1.70M
Employee Count28
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Q32 Bio is ―. Q32 Bio’s PEG ratio is 0.01.
PE Ratio―
PS Ratio0.00
PB Ratio7.39
Price to Fair Value7.39
Price to FCF-0.62
Price to Operating Cash Flow-0.64
PEG Ratio0.01
Income Statement
In the last 12 months, Q32 Bio had revenue of 0.00 and earned -47.73M in profits. Earnings per share was -5.12.
Revenue0.00
Gross Profit-487.00K
Operating Income-66.10M
Pretax Income-47.71M
Net Income-47.73M
EBITDA-45.30M
Earnings Per Share (EPS)-5.12
Cash Flow
In the last 12 months, operating cash flow was -38.79M and capital expenditures -2.00K, giving a free cash flow of -38.79M billion.
Operating Cash Flow-38.79M
Free Cash Flow-38.79M
Free Cash Flow per Share-3.15
Dividends & Yields
Q32 Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.76
52-Week Price Change-4.76%
50-Day Moving Average2.79
200-Day Moving Average2.12
Relative Strength Index (RSI)56.61
Average Volume (3m)396.43K
Important Dates
Q32 Bio upcoming earnings date is Mar 17, 2026, After Close (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateMar 17, 2026
Ex-Dividend Date―
Financial Position
Q32 Bio as a current ratio of 4.97, with Debt / Equity ratio of -61.54%
Current Ratio4.97
Quick Ratio4.97
Debt to Market Cap0.30
Net Debt to EBITDA1.30
Interest Coverage Ratio-220.34
Taxes
In the past 12 months, Q32 Bio has paid 21.00K in taxes.
Income Tax21.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Q32 Bio EV to EBITDA ratio is 0.38, with an EV/FCF ratio of 0.25.
EV to Sales0.00
EV to EBITDA0.38
EV to Free Cash Flow0.25
EV to Operating Cash Flow0.25
Balance Sheet
Q32 Bio has $49.04M in cash and marketable securities with $11.35M in debt, giving a net cash position of $37.69M billion.
Cash & Marketable Securities$49.04M
Total Debt$11.35M
Net Cash$37.69M
Net Cash Per Share$3.06
Tangible Book Value Per Share$0.47
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Q32 Bio is $15.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$15.00
Price Target Upside368.75% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast49.57%